Vaxcyte 

Yahoo Finance • 11 days ago

Impressive Clinical Pipeline Leads to Bullish Sentiment for Vaxcyte (PCVX)

Vaxcyte Incorporated (NASDAQ:PCVX) is one of the 17 biotechnology stocks with more than 50% upside. On January 23, Cantor Fitzgerald maintained its Overweight rating on Vaxcyte Incorporated (NASDAQ:PCVX), highlighting continued progress a... Full story

Yahoo Finance • 16 days ago

Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines

Vaxcyte, Inc. Company Expects to Report Topline Data from OPUS-3 Trial and OPUS-2 Phase 3 Trial Evaluating Concomitant Administration of VAX-31 and a Seasonal Influenza Vaccine in First Half of 2027 OPUS-1, VAX-31 Adult Phase 3 Noninferi... Full story

Yahoo Finance • 25 days ago

Vaxcyte Funding And Late-Stage Trials Put Valuation In Focus

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Vaxcyte (NasdaqGS:PCVX) has completed a major public equity offering, adding fresh capital to it... Full story

Yahoo Finance • 2 months ago

What Makes Vaxcyte (PCVX) So Attractive

Vaxcyte Inc. (NASDAQ:PCVX) is one of the most promising mid-cap healthcare stocks under $50. On December 9, BTIG analyst Thomas Shrader reiterated his bullish view of Vaxcyte Inc. (NASDAQ:PCVX). He assigned a Buy rating to the stock with... Full story

Yahoo Finance • 3 months ago

Vaxcyte, Inc. (PCVX) Makes Strides on Pneumonia Treatment, Plots Coverage Extension

Vaxcyte, Inc. (NASDAQ:PCVX) is one of the best biotech stocks to buy, according to Wall Street analysts. On December 8, the company confirmed the dosing of the first patients in its Phase 3 OPUS trial. The company is evaluating VAX-31 in t... Full story

Yahoo Finance • 3 months ago

These stocks are new additions to Mizuho’s ’Americas Top Picks’ list

Investing.com -- Mizuho has refreshed its monthly Americas Top Picks list, adding new high-conviction ideas selected by its U.S. equity analysts. The list highlights “our analysts’ highest conviction, catalyst-driven ideas,” Mizuho says,... Full story

Yahoo Finance • 3 months ago

IMU Biosciences Appoints Dr. Carlos Paya as Non-Executive Director, Strengthening its Board of Directors

IMU Biosciences PRESS RELEASE London, UK, 20 November 2025 — IMU Biosciences (or “the Company”), a biotechnology company decoding the immune system to drive next generation health outcomes, today announced the appointment of Dr. Carlos P... Full story

Yahoo Finance • 3 months ago

Medicxi Announces €500 Million Fund V

New fund will continue Medicxi's successful asset-centric company creation and investment strategy. LONDON, Nov. 14, 2025 /PRNewswire/ -- Medicxi, a leading European life sciences venture capital firm, today announced the closing of Medic... Full story

Yahoo Finance • 4 months ago

Vaxcyte Reports Third Quarter 2025 Financial Results and Provides Business Update Including Final Data from Positive VAX-24 Infant Phase 2 Dose-Finding Study

Final Data from VAX-24 Infant Phase 2 Dose-Finding Study Consistent with Previously Reported Positive Interim Data; Provide Additional Evidence Supporting Higher VAX-31 Doses Being Evaluated in Ongoing Infant Phase 2 Study Modified VAX-31... Full story

Yahoo Finance • 4 months ago

HAL Crosses Above Key Moving Average Level

In trading on Friday, shares of Halliburton Company (Symbol: HAL) crossed above their 200 day moving average of $34.20, changing hands as high as $35.77 per share. Halliburton Company shares are currently trading up about 8.3% on the day.... Full story

Yahoo Finance • 5 months ago

Can Thermo Fisher (TMO) Balance Biomanufacturing Expansion and AI Ambitions to Shape Its Long-Term Edge?

Vaxcyte announced a new agreement with Thermo Fisher Scientific to provide up to US$1 billion in long-term commercial fill-finish capacity for pneumococcal conjugate vaccines at Thermo Fisher's Greenville, North Carolina facility. Thermo F... Full story

Yahoo Finance • 5 months ago

Thermo Fisher (TMO) Stock Trades Up, Here Is Why

What Happened? Shares of life sciences company Thermo Fisher (NYSE:TMO) jumped 9% in the afternoon session after the company secured a major manufacturing agreement with biotechnology firm Vaxcyte and announced a new AI-focused partnershi... Full story

Yahoo Finance • 6 months ago

Vaxcyte Advances VAX-31 Infant Phase 2 Dose-Finding Study with First Participants Receiving VAX-31 Optimized Dose

VAX-31 Optimized Dose, with Majority of Serotypes Dosed at 4.4mcg and Balance at 3.3mcg, is Designed to Elicit Even Stronger Immune Responses in Infant Population to Protect Against Invasive Pneumococcal Disease (IPD) Company Intends to R... Full story

Yahoo Finance • 7 months ago

Vaxcyte Becomes Oversold (PCVX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the R... Full story

Yahoo Finance • 7 months ago

Mizuho Maintains an Overweight Rating on Vaxcyte (PCVX)

Vaxcyte, Inc. (NASDAQ:PCVX) is one of the best oversold NASDAQ stocks to buy now. On June 20, Mizuho analyst Salim Syed commented on Vaxcyte, Inc. (NASDAQ:PCVX), on which the firm maintained an Outperform rating. Syed’s comment followed re... Full story

Yahoo Finance • 8 months ago

Here’s Why Vaxcyte (PCVX) Sold Off in Q1

PGIM Jennison Health Sciences Fund released its first quarter 2025 investor letter. A copy of the letter can be downloaded here. The S&P 1500 Health Care Index returned 5.5% in the first quarter, outperforming the S&P 500’s -4.3% return. B... Full story

Yahoo Finance • 11 months ago

Vaxcyte, Inc. (PCVX): One of the Best Debt Free Mid Cap Stocks to Buy Now

We recently compiled a list of the 10 Best Debt Free Mid Cap Stocks to Buy Now. In this article, we are going to take a look at where Vaxcyte, Inc. (NASDAQ:PCVX) stands against the other debt free mid cap stocks. Debt-free mid-cap stocks... Full story

Yahoo Finance • 11 months ago

Vaxcyte to Host Webcast and Conference Call to Present Topline Results from VAX-24 Infant Phase 2 Study

SAN CARLOS, Calif., March 30, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today a... Full story

Yahoo Finance • 11 months ago

Why Vaxcyte, Inc. (PCVX) Is Among the Best Mid Cap Biotech Stocks to Buy

We recently published a list of the 10 Best Mid Cap Biotech Stocks to Buy. In this article, we are going to take a look at where Vaxcyte, Inc. (NASDAQ:PCVX) stands against the other best mid cap biotech stocks to buy. Is the Biotech Secto... Full story

Yahoo Finance • last year

Vaxcyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

-- Completed Successful VAX-31 Phase 2 Adult Program; Company Remains on Track to Initiate VAX-31 Adult Phase 3 Pivotal, Non-Inferiority Study by Mid-2025 and Announce Topline Safety, Tolerability and Immunogenicity Data in 2026 -- -- Com... Full story